Rikkunshi-to Partially Reverses Cancer Chemotherapy-Induced Decrease in Plasma Valproic Acid Concentration in a Patient with Malignant Lymphoma
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Abstract
A fifty-five-year-old male patient with malignant lymphoma who took oral valproic acid (VPA) tablets and itraconazole (ITZ) capsles received 3 courses of cancer chemotherapy, including 2 courses of a combination of rituximab/methotrexate/ifosphamide/etoposide/ carboplatin/ methylpredonisolon (R-IMVP16/CBDCA regimen) and subsequent one course of a combination of rituximab/ranimustine/citara bine/etoposide/merphalan (R-MEAM regimen). Plasma concentration of VPA dramatically decreased below the therapeutic concentration after the first and second chemotherapy and seizures appeared in both cases. Plasma concentration of ITZ was also lowered after the second chemotherapy course. At the third chemotherapy, Rikkunshi-to, a Japanese herbal medicine, was prescribed for 14 days. Plasma VPA concentration decreased, though to a lesser extent, after chemotherapy, in which the level was near the border of therapeutic concentration. No convulsion was observed. Therefore, care should be taken to monitor plasma drug concentration during cancer chemotherapy. Rikkunshi-to may be useful to alleviate the chemotherapy-induced decrease in plasma concentrations of orally administered drugs.
- R. Gugler and G. E. Von Unruh, “Clinical Pharmacokinetics of Valproic Acid,” Clinical Pharmacokinetics, Vol. 5, No. 1, January -February 1980, pp. 67-83. doi:10.2165/00003088-198005010-00002
- J. O. Miners, “Drug Interactions Involving Aspirin (Acetylsalicylic Acid) and Salicylic Acid,” Clinical Pharmacokinetics, Vol. 17, No. 5, November 1989, pp. 327-344. doi:10.2165/00003088-198917050-00003
- E. Kingsley, R. Tweedale and K. G. Tolman, “Hepatotoxicity of Sodium Valproate and Other Anticonvulsants in Rat Hepatocyte Cultures,” Epilepsia, Vol. 21, No. 6, December 1980, pp. 699-704.
- D. Haidukewych and E. A. Rodin, “Monitoring Free Valproic Acid in Epilepsy Patients Medicated with Coanticonvulsants,” Therapeutic Drug Monitoring, Vol. 4, No. 2, February 1982, pp. 209-212. doi:10.1097/00007691-198206000-00009
- M. Torii, Y. Takiguchi, F. Saito, M. Izumi and M. Yokota, “Inhibition by Carbapenem Antibiotic Imipenem of Intestinal Absorption of Valproic Acid in Rats,” Journal of Pharmacy and Pharmacology, Vol. 53, No. 6, June 2001, pp. 823-829. doi:10.1211/0022357011776171
- H. Mori, K. Takahashi and T. Mizutani, “Interaction between Valproic Acid and Carbapenem Antibiotics,” Drug Metabolism Review, Vol. 39, No. 4, April 2007, pp. 647- 657. doi:10.1080/03602530701690341
- Y. Nakamura, K. Nakahira and T. Mizutani, “Decreased Valproate Level Caused by VPA-Glucuronidase Inhibition by Carbapenem Antibiotics,” Drug Metabolism Letters, Vol. 2, No. 4, December 2008, pp. 280-285. doi:10.2174/187231208786734049
- E. E. Mancl and B. E. Gidal, “The Effect of Carbapenem Antibiotics on Plasma Concentrations of Valproic Acid,” Annals of Pharmacotherapy, Vol. 43, No. 12, December 2009, pp. 2082- 2087. doi:10.1345/aph.1M296
- D. Battino, D. Croci, T. Granata, M. Estienne, F. Pisani and G. Avanzini, “Lamotrigine Plasma Concentrations in Children and Adults: Influence of Age and Associated Therapy,” Therapeutic Drug Monitoring, Vol. 19, No. 6, December 1997, pp. 620-627. doi:10.1097/00007691-199712000-00003
- J. M. Orr, F. S. Abbott, K. Farrell, S. Ferguson, I. Sheppard and W. Godolphin, “Interaction between Valproic Acid and Aspirin in Epileptic Children: Serum Protein Binding and Metabolic Effects,” Clinical Pharmacology and Therapeutics, Vol. 31, No. 5, May 1982, pp. 642-649. doi:10.1038/clpt.1982.89
- H. Kutt, “Interactions between Anticonvulsants and Other Commonly Prescribed Drugs,” Epilepsia, Vol. 25, No. 3 Suppl. 2, 1984, pp. S118-S131. doi:10.1111/j.1528-1157.1984.tb05644.x